Philips Introduces Next-Generation Digital Pathology Solution with Integrated AI Tools and Algorithms
|
By LabMedica International staff writers Posted on 18 Oct 2021 |
|
Royal Philips (Amsterdam, the Netherlands) has launched its next-generation digital pathology solution, moving digital pathology into the heart of enterprise-wide healthcare informatics.
Precision medicine has increased the volume and complexity of workloads, with pathology labs worldwide facing a shortage of skilled staff. Within the diagnosis and staging of cancer, pathology information is combined with data from multiple disciplines, including radiology, pathology and genomics, to deliver the diagnostic precision required for highly personalized care. There is an urgent need for solutions that combine operational efficiency, team-working, expertise sharing, and enterprise-wide informatics to make the most of a pathology lab’s human resources.
Through breakthrough innovations and partnerships, Philips integrates intelligence and automation into its Precision Diagnosis portfolio, including smart diagnostic systems, integrated workflow solutions with the aim to transform departmental operations, advanced informatics that enhance diagnostic confidence, and care pathway solutions that allow medical professionals to tailor treatment to individual patients. By developing and integrating AI-enabled applications, the company aims to enhance the ability to turn data into actionable insights and drive the right care in the right sequence at the right time.
Philips Digital Pathology Suite - IntelliSite - features a comprehensive, scalable suite of software tools and capabilities designed to help streamline workflows, enhance diagnostic confidence, facilitate team collaboration, integrate artificial intelligence (AI) and increase the efficiency of pathology labs. Philips Digital Pathology Suite offers a range of solutions designed for different use cases with an affordable cost of ownership. From low-volume ‘spoke’ labs or small independent labs, where small batches of slides are continually processed and scanned, to medium and large labs operating high-volume batch processing workflows. The hardware is also pre-equipped for multi-layer slide scanning. Images are captured in a centralized informatics platform that has been optimized around pathologists’ workflows, integrating with leading third-party AI tools and algorithms with the aim to further reduce laboratory costs and enhance diagnostic capabilities.
Digital Pathology Suite includes a range of three pathology slide scanners, as well as Pathology Workspace - Image Management System - a comprehensive set of software tools and capabilities that encompass every stage of the digital pathology process, including an advanced image management system, bidirectional interoperability into laboratory information systems, and a case viewer that facilitates multidisciplinary case reviews and care pathway selection. Diagnostic confidence is enhanced by superb image quality and advanced algorithms, such as automatic tissue shape detection and non-rectangular optimization of regions of interest. Vendor-agnostic data interoperability also allows the easy sharing of patient-centric histology data across enterprises and between sites.
"Integrated diagnostic capabilities are a cornerstone to a precise diagnosis and personalized care pathway selection for oncology patients and only when data and specialties work together in harmony can the ultimate promise of care be realized,” said Louis Culot, General Manager Oncology Informatics at Philips. “That’s why bringing together multiple pieces of the healthcare continuum – like radiology, pathology, and genomics – is the key to a new paradigm of diagnostic precision. By providing pathologists the interoperability and connectivity to share high-quality images and diagnostic insights across networks, Philips Digital Pathology Suite positions them as key stakeholders in the data-driven healthcare systems of the future.”
Related Links:
Royal Philips
 Assay.jpg)
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channel
Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
Molecular Diagnostics
view channel
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read more
Hematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Technology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
